VCG
XLRN

Vantage Consulting Group’s Acceleron Pharma XLRN Stock Holding History

Vantage Consulting Group’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-7
Closed -$1K – 1807
2020
Q4 		$1K Buy
+7
New +$821 ﹤0.01% 1851

Other funds holding XLRN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vantage Consulting Group's XLRN Position: Q1 2021 in Review

Vantage Consulting Group sold out of Acceleron Pharma (XLRN) in Q1 2021, closing a stake of 7 shares — an estimated $1K sold.

Vantage Consulting Group first reported a position in XLRN in Q4 2020 and held it in 1 quarter. The position peaked at $1K in Q4 2020. 256 funds tracked by Wall St. Rank hold XLRN as of Q1 2021.

  • Vantage Consulting Group reported no remaining Acceleron Pharma position as of Q1 2021 after selling out during the quarter.
  • Vantage Consulting Group sold 7 Acceleron Pharma shares in Q1 2021, an estimated $1K.
  • Vantage Consulting Group first reported a position in Acceleron Pharma in Q4 2020 and held it in 1 quarter.
  • Vantage Consulting Group's Acceleron Pharma position peaked at $1K in Q4 2020.
  • 256 funds tracked by Wall St. Rank held Acceleron Pharma as of Q1 2021.

Based on Vantage Consulting Group's 13F filing for Q1 2021, filed 14 May 2021.